Market closed

Illumina/$ILMN

14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX

About Illumina

Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (9% of 2023 sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.

Ticker

$ILMN
Sector
Health Care
Trading on
NASDAQ

Industry

Life Sciences Tools & Services
Headquarters
San Diego, United States

Employees

10,615
Website
www.illumina.com

Illumina Metrics

BasicAdvanced
$23B
-
-$9.98
1.13
-

$23B

1.13

$156.66

$100.09

1.9M

2.434

1.696

122.4

125.835

3.63%

2.62%

-39.51%

5.215

10.79

32.43

41.932

-1.68%

40.00%

0.85%

17.80%

What the Analysts think about Illumina

Analyst Ratings

Analyst ratings (Buy, Hold, Sell) for Illumina stock.

Illumina Financial Performance

Income Statement

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

Illumina Earnings Performance

Earnings per share (EPS)

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-

Illumina News

AllArticlesVideos
Illumina, Inc. (ILMN) 43rd Annual JPMorgan Healthcare Conference - (Transcript)

Illumina, Inc. (ILMN) 43rd Annual JPMorgan Healthcare Conference - (Transcript)

Seeking Alpha·13 hours ago
Truveta sells stakes to Regeneron, Illumina in deal to build genetic database

Truveta sells stakes to Regeneron, Illumina in deal to build genetic database

Reuters·2 days ago
Illumina, Inc. (ILMN) CFO Ankur Dhingra Hosts Annual Evercore ISI HealthCONx Healthcare Conference (Transcript)

Illumina, Inc. (ILMN) CFO Ankur Dhingra Hosts Annual Evercore ISI HealthCONx Healthcare Conference (Transcript)

Seeking Alpha·1 month ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $ILMN

$

Sign up or log in to buy
Capital at risk
Market closed

Upcoming events

No upcoming events

FAQs

What’s the current market cap for Illumina stock?

Illumina (ILMN) has a market cap of $23B as of January 15, 2025.

What is the P/E ratio for Illumina stock?

The price to earnings (P/E) ratio for Illumina (ILMN) stock is 0 as of January 15, 2025.

Does Illumina stock pay dividends?

No, Illumina (ILMN) stock does not pay dividends to its shareholders as of January 15, 2025.

When is the next Illumina dividend payment date?

Illumina (ILMN) stock does not pay dividends to its shareholders.

What is the beta indicator for Illumina?

Illumina (ILMN) has a beta rating of 1.13. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.